vs
AVANOS MEDICAL, INC.（AVNS）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Rocket Lab Corp的1.0倍（$180.9M vs $179.7M），AVANOS MEDICAL, INC.净利率更高（-0.7% vs -29.5%，领先28.7%），Rocket Lab Corp同比增速更快（35.7% vs 0.7%），AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
AVNS vs RKLB — 直观对比
营收规模更大
AVNS
是对方的1.0倍
$179.7M
营收增速更快
RKLB
高出35.0%
0.7%
净利率更高
AVNS
高出28.7%
-29.5%
自由现金流更多
AVNS
多$135.5M
$-114.2M
两年增速更快
RKLB
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $179.7M |
| 净利润 | $-1.3M | $-52.9M |
| 毛利率 | 47.5% | 38.0% |
| 营业利润率 | 1.4% | -28.4% |
| 净利率 | -0.7% | -29.5% |
| 营收同比 | 0.7% | 35.7% |
| 净利润同比 | 99.7% | -1.1% |
| 每股收益（稀释后） | $-0.02 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRKLB
| Q4 25 | $180.9M | $179.7M | ||
| Q3 25 | $177.8M | $155.1M | ||
| Q2 25 | $175.0M | $144.5M | ||
| Q1 25 | $167.5M | $122.6M | ||
| Q4 24 | $179.6M | $132.4M | ||
| Q3 24 | $170.4M | $104.8M | ||
| Q2 24 | $171.7M | $106.3M | ||
| Q1 24 | $166.1M | $92.8M |
净利润AVNSRKLB
| Q4 25 | $-1.3M | $-52.9M | ||
| Q3 25 | $-1.4M | $-18.3M | ||
| Q2 25 | $-76.8M | $-66.4M | ||
| Q1 25 | $6.6M | $-60.6M | ||
| Q4 24 | $-397.3M | $-52.3M | ||
| Q3 24 | $4.3M | $-51.9M | ||
| Q2 24 | $1.8M | $-41.6M | ||
| Q1 24 | $-900.0K | $-44.3M |
毛利率AVNSRKLB
| Q4 25 | 47.5% | 38.0% | ||
| Q3 25 | 48.4% | 37.0% | ||
| Q2 25 | 52.6% | 32.1% | ||
| Q1 25 | 53.6% | 28.8% | ||
| Q4 24 | 54.6% | 27.8% | ||
| Q3 24 | 54.5% | 26.7% | ||
| Q2 24 | 55.7% | 25.6% | ||
| Q1 24 | 57.1% | 26.1% |
营业利润率AVNSRKLB
| Q4 25 | 1.4% | -28.4% | ||
| Q3 25 | 0.1% | -38.0% | ||
| Q2 25 | -42.6% | -41.3% | ||
| Q1 25 | 6.1% | -48.3% | ||
| Q4 24 | -233.0% | -38.9% | ||
| Q3 24 | 7.0% | -49.5% | ||
| Q2 24 | 3.7% | -40.7% | ||
| Q1 24 | 2.4% | -46.4% |
净利率AVNSRKLB
| Q4 25 | -0.7% | -29.5% | ||
| Q3 25 | -0.8% | -11.8% | ||
| Q2 25 | -43.9% | -46.0% | ||
| Q1 25 | 3.9% | -49.5% | ||
| Q4 24 | -221.2% | -39.5% | ||
| Q3 24 | 2.5% | -49.6% | ||
| Q2 24 | 1.0% | -39.2% | ||
| Q1 24 | -0.5% | -47.7% |
每股收益（稀释后）AVNSRKLB
| Q4 25 | $-0.02 | $-0.09 | ||
| Q3 25 | $-0.03 | $-0.03 | ||
| Q2 25 | $-1.66 | $-0.13 | ||
| Q1 25 | $0.14 | $-0.12 | ||
| Q4 24 | $-8.64 | $-0.11 | ||
| Q3 24 | $0.09 | $-0.10 | ||
| Q2 24 | $0.04 | $-0.08 | ||
| Q1 24 | $-0.02 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $1.0B |
| 总债务越低越好 | $90.3M | $152.4M |
| 股东权益账面价值 | $778.2M | $1.7B |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资AVNSRKLB
| Q4 25 | $89.8M | $1.0B | ||
| Q3 25 | $70.5M | $976.7M | ||
| Q2 25 | $90.3M | $688.1M | ||
| Q1 25 | $97.0M | $428.4M | ||
| Q4 24 | $107.7M | $419.0M | ||
| Q3 24 | $89.0M | $442.4M | ||
| Q2 24 | $92.2M | $496.8M | ||
| Q1 24 | $75.8M | $492.5M |
总债务AVNSRKLB
| Q4 25 | $90.3M | $152.4M | ||
| Q3 25 | $93.4M | $347.0M | ||
| Q2 25 | $95.7M | $346.5M | ||
| Q1 25 | $98.0M | $345.9M | ||
| Q4 24 | $125.3M | $345.4M | ||
| Q3 24 | $152.6M | $61.2M | ||
| Q2 24 | $164.9M | $64.2M | ||
| Q1 24 | $167.2M | $66.8M |
股东权益AVNSRKLB
| Q4 25 | $778.2M | $1.7B | ||
| Q3 25 | $778.0M | $1.3B | ||
| Q2 25 | $776.3M | $688.5M | ||
| Q1 25 | $839.4M | $431.3M | ||
| Q4 24 | $828.5M | $382.5M | ||
| Q3 24 | $1.2B | $419.8M | ||
| Q2 24 | $1.2B | $455.2M | ||
| Q1 24 | $1.2B | $478.9M |
总资产AVNSRKLB
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
负债/权益比AVNSRKLB
| Q4 25 | 0.12× | 0.09× | ||
| Q3 25 | 0.12× | 0.27× | ||
| Q2 25 | 0.12× | 0.50× | ||
| Q1 25 | 0.12× | 0.80× | ||
| Q4 24 | 0.15× | 0.90× | ||
| Q3 24 | 0.12× | 0.15× | ||
| Q2 24 | 0.13× | 0.14× | ||
| Q1 24 | 0.14× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $-114.2M |
| 自由现金流率自由现金流/营收 | 11.8% | -63.6% |
| 资本支出强度资本支出/营收 | 3.8% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流AVNSRKLB
| Q4 25 | $28.2M | $-64.5M | ||
| Q3 25 | $14.0M | $-23.5M | ||
| Q2 25 | $6.8M | $-23.2M | ||
| Q1 25 | $25.7M | $-54.2M | ||
| Q4 24 | $57.9M | $-2.4M | ||
| Q3 24 | $23.0M | $-30.9M | ||
| Q2 24 | $27.8M | $-13.0M | ||
| Q1 24 | $-8.0M | $-2.6M |
自由现金流AVNSRKLB
| Q4 25 | $21.3M | $-114.2M | ||
| Q3 25 | $7.0M | $-69.4M | ||
| Q2 25 | $-4.2M | $-55.3M | ||
| Q1 25 | $19.0M | $-82.9M | ||
| Q4 24 | $53.1M | $-23.9M | ||
| Q3 24 | $20.0M | $-41.9M | ||
| Q2 24 | $21.9M | $-28.3M | ||
| Q1 24 | $-12.1M | $-21.8M |
自由现金流率AVNSRKLB
| Q4 25 | 11.8% | -63.6% | ||
| Q3 25 | 3.9% | -44.8% | ||
| Q2 25 | -2.4% | -38.3% | ||
| Q1 25 | 11.3% | -67.6% | ||
| Q4 24 | 29.6% | -18.1% | ||
| Q3 24 | 11.7% | -40.0% | ||
| Q2 24 | 12.8% | -26.7% | ||
| Q1 24 | -7.3% | -23.5% |
资本支出强度AVNSRKLB
| Q4 25 | 3.8% | 27.6% | ||
| Q3 25 | 3.9% | 29.6% | ||
| Q2 25 | 6.3% | 22.2% | ||
| Q1 25 | 4.0% | 23.4% | ||
| Q4 24 | 2.7% | 16.3% | ||
| Q3 24 | 1.8% | 10.5% | ||
| Q2 24 | 3.4% | 14.4% | ||
| Q1 24 | 2.5% | 20.7% |
现金转化率AVNSRKLB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
